+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biologics Outsourcing Market by Product Type, Application, Source, Service Type, End User, Therapeutic Area - Global Forecast 2025-2030- Product Image
Biologics Outsourcing Market by Product Type, Application, Source, Service Type, End User, Therapeutic Area - Global Forecast 2025-2030- Product Image
Sale

Biologics Outsourcing Market by Product Type, Application, Source, Service Type, End User, Therapeutic Area - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6011402
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biologics Outsourcing Market grew from USD 20.56 billion in 2023 to USD 22.87 billion in 2024. It is expected to continue growing at a CAGR of 12.18%, reaching USD 45.98 billion by 2030.

Biologics outsourcing encompasses the delegation of manufacturing, clinical research, and development tasks of biologic drugs to third-party organizations, often by pharmaceutical companies seeking to optimize costs and access specialized expertise. This practice has become indispensable in the biologics sector due to the high complexity and intensive resource requirements of biologic production. Outsourcing is crucial for applications that range from monoclonal antibodies to vaccines, as it facilitates scalable production and shortens time-to-market. The end-use scope predominantly includes pharmaceuticals and biotechnology firms, which benefit from the advanced technologies and experience that Contract Development and Manufacturing Organizations (CDMOs) offer. Key growth drivers include the rising demand for biologics globally, which is fueled by an increasing prevalence of chronic diseases and the need for more effective therapies. Additionally, advancements in biologics-related technologies, like single-use bioprocessing and cell line development, present promising opportunities for stakeholders. To capitalize on these, firms should invest in partnership-building, strategic alliances, and fostering innovations around rapid development and production techniques. However, the biologics outsourcing market faces limitations due to stringent regulatory environments and high initial investment requirements. The lack of skilled professionals and challenges in maintaining product quality and consistency also pose significant barriers. Areas ripe for innovation include the enhancement of biomanufacturing processes, bioinformatics, and personalized medicine approaches, which can dramatically alter production efficiency and therapeutic outcomes. The market exhibits a dynamic and competitive nature with a strong trend towards strategic collaborations and capacity expansions to cater to the growing demand. To thrive, businesses should focus on diversifying their service offerings, ensuring compliance with regulatory standards, and investing in staff training to overcome skill shortages, all while strategically navigating and leveraging the emerging technological advancements in the biologics space.

Understanding Market Dynamics in the Biologics Outsourcing Market

The Biologics Outsourcing Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Stringent regulatory requirements and the need for compliance expertise in biologics production
    • Cost-efficiency and time reduction benefits driving outsourcing of biologics manufacturing
    • Expansion of biologics pipelines by pharmaceutical companies necessitating external manufacturing support
    • Adoption of single-use technologies and continuous bioprocessing by outsourcing firms
  • Market Restraints
    • Limited availability of skilled workforce for specialized biologics manufacturing and process development
    • Variability in biological product quality during outsourcing leading to potential risks and liabilities
  • Market Opportunities
    • Partnership opportunities with smaller biotechnology firms seeking affordable biologics manufacturing solutions
    • Growing need for specialized biologics development services in niche therapeutic areas
    • Rising collaboration between pharmaceutical companies and contract research organizations for biologics development
  • Market Challenges
    • Managing supply chain disruptions and logistics challenges in the biologics outsourcing market
    • Ensuring cost efficiency while maintaining high quality standards in biologics outsourcing services

Exploring Porter’s Five Forces for the Biologics Outsourcing Market

Porter’s Five Forces framework further strengthens the insights of the Biologics Outsourcing Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Biologics Outsourcing Market

External macro-environmental factors deeply influence the performance of the Biologics Outsourcing Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Biologics Outsourcing Market

The Biologics Outsourcing Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Biologics Outsourcing Market

The Biologics Outsourcing Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Biologics Outsourcing Market

The Biologics Outsourcing Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Outsourcing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Biocon Limited, Boehringer Ingelheim GmbH, Catalent, Inc., Charles River Laboratories International, Inc., Covance Inc., Eli Lilly and Company, Fujifilm Diosynth Biotechnologies, Genentech, Inc., Icon plc, Lonza Group AG, Merck KGaA, Novartis AG, Parexel International Corporation, Pfizer Inc., Samsung Biologics Co., Ltd., Sandoz International GmbH, Thermo Fisher Scientific Inc., and WuXi AppTec Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Biologics Outsourcing Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product Type
    • Antisense, RNAi, And Molecular Therapy
    • Monoclonal Antibodies
    • Other Biologics
    • Recombinant Proteins
    • Vaccines
  • Application
    • Cardiovascular Diseases
    • Immunology
      • Allergic Disorders
      • Autoimmune Diseases
    • Infectious Diseases
      • Bacterial Infections
      • Viral Infections
    • Neurology
    • Oncology
      • Cancer Biomarker Studies
      • Personalized Cancer Treatments
    • Other Applications
  • Source
    • Mammalian
    • Non-Mammalian
      • Bacteria
      • Insect Cells
      • Plant Cells
      • Yeast
  • Service Type
    • Analytical And Quality Control
    • Clinical Trials
    • Fill And Finish Operations
    • Process Development
    • Regulatory Services
  • End User
    • Biotechnology Companies
    • Contract Research Organizations (CROs)
    • Pharmaceutical Companies
    • Research Institutes
  • Therapeutic Area
    • Cancer
    • Cardiovascular Diseases
    • Infectious Diseases
    • Inflammatory And Immune Disorders
    • Metabolic Disorders
    • Neurological Conditions
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Stringent regulatory requirements and the need for compliance expertise in biologics production
5.1.1.2. Cost-efficiency and time reduction benefits driving outsourcing of biologics manufacturing
5.1.1.3. Expansion of biologics pipelines by pharmaceutical companies necessitating external manufacturing support
5.1.1.4. Adoption of single-use technologies and continuous bioprocessing by outsourcing firms
5.1.2. Restraints
5.1.2.1. Limited availability of skilled workforce for specialized biologics manufacturing and process development
5.1.2.2. Variability in biological product quality during outsourcing leading to potential risks and liabilities
5.1.3. Opportunities
5.1.3.1. Partnership opportunities with smaller biotechnology firms seeking affordable biologics manufacturing solutions
5.1.3.2. Growing need for specialized biologics development services in niche therapeutic areas
5.1.3.3. Rising collaboration between pharmaceutical companies and contract research organizations for biologics development
5.1.4. Challenges
5.1.4.1. Managing supply chain disruptions and logistics challenges in the biologics outsourcing market
5.1.4.2. Ensuring cost efficiency while maintaining high quality standards in biologics outsourcing services
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Biologics Outsourcing Market, by Product Type
6.1. Introduction
6.2. Antisense, RNAi, And Molecular Therapy
6.3. Monoclonal Antibodies
6.4. Other Biologics
6.5. Recombinant Proteins
6.6. Vaccines
7. Biologics Outsourcing Market, by Application
7.1. Introduction
7.2. Cardiovascular Diseases
7.3. Immunology
7.3.1. Allergic Disorders
7.3.2. Autoimmune Diseases
7.4. Infectious Diseases
7.4.1. Bacterial Infections
7.4.2. Viral Infections
7.5. Neurology
7.6. Oncology
7.6.1. Cancer Biomarker Studies
7.6.2. Personalized Cancer Treatments
7.7. Other Applications
8. Biologics Outsourcing Market, by Source
8.1. Introduction
8.2. Mammalian
8.3. Non-Mammalian
8.3.1. Bacteria
8.3.2. Insect Cells
8.3.3. Plant Cells
8.3.4. Yeast
9. Biologics Outsourcing Market, by Service Type
9.1. Introduction
9.2. Analytical And Quality Control
9.3. Clinical Trials
9.4. Fill And Finish Operations
9.5. Process Development
9.6. Regulatory Services
10. Biologics Outsourcing Market, by End User
10.1. Introduction
10.2. Biotechnology Companies
10.3. Contract Research Organizations (CROs)
10.4. Pharmaceutical Companies
10.5. Research Institutes
11. Biologics Outsourcing Market, by Therapeutic Area
11.1. Introduction
11.2. Cancer
11.3. Cardiovascular Diseases
11.4. Infectious Diseases
11.5. Inflammatory And Immune Disorders
11.6. Metabolic Disorders
11.7. Neurological Conditions
12. Americas Biologics Outsourcing Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Biologics Outsourcing Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Biologics Outsourcing Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. BIOLOGICS OUTSOURCING MARKET RESEARCH PROCESS
FIGURE 2. BIOLOGICS OUTSOURCING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
FIGURE 17. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 21. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. BIOLOGICS OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 27. BIOLOGICS OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. BIOLOGICS OUTSOURCING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BIOLOGICS OUTSOURCING MARKET DYNAMICS
TABLE 7. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ANTISENSE, RNAI, AND MOLECULAR THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY OTHER BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ALLERGIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CANCER BIOMARKER STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PERSONALIZED CANCER TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY OTHER APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INSECT CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ANALYTICAL AND QUALITY CONTROL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILL AND FINISH OPERATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGULATORY SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFLAMMATORY AND IMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 86. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 87. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 89. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 90. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 91. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 92. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 93. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 94. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 96. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 99. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 100. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 101. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 102. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 103. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 104. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 120. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 122. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 129. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 132. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 133. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 134. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 135. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 136. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 138. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 139. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 141. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 142. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 143. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 144. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 145. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 146. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 148. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 149. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 151. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 152. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 153. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 154. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 155. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 156. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 158. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 159. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 162. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 163. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 164. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 165. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 166. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 168. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 169. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 171. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 172. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 173. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 174. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 175. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 176. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 179. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 181. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 182. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 183. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 184. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 185. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 186. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 188. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 189. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 191. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 192. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 193. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 194. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 195. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 196. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 198. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 201. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 202. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 203. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 204. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 205. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 206. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 208. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 209. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 210. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 211. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 212. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 213. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 214. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 215. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 216. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 218. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 219. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 222. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 223. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 224. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 225. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 226. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 228. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 229. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 231. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 232. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 233. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 234. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 235. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 236. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 238. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 239. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 241. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 242. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 243. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 244. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 245. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 246. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 259. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 260. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 262. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 263. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 264. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 265. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 266. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 267. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 269. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 270. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 271. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 272. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 273. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 274. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 275. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 276. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 277. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 279. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 280. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 281. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 282. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 283. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 284. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 285. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 286. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 287. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 289. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 290. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 291. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 292. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 293. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 294. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 295. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 296. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 297. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 299. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 300. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 301. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 302. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 303. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 304. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 305. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 306. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 307. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 309. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 310. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 311. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 312. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 316. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 319. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 320. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 321. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 322. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 323. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 324. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 325. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 326. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 327. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 328. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 329. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 330. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 331. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 332. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 333. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 334. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 335. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 336. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 337. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 338. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 339. NIGERIA BIOLOGICS

Companies Mentioned

The leading players in the Biologics Outsourcing market, which are profiled in this report, include:
  • AbbVie Inc.
  • Amgen Inc.
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Covance Inc.
  • Eli Lilly and Company
  • Fujifilm Diosynth Biotechnologies
  • Genentech, Inc.
  • Icon plc
  • Lonza Group AG
  • Merck KGaA
  • Novartis AG
  • Parexel International Corporation
  • Pfizer Inc.
  • Samsung Biologics Co., Ltd.
  • Sandoz International GmbH
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 22.87 Billion
Forecasted Market Value ( USD ) by 2030 $ 45.98 Billion
Compound Annual Growth Rate12.1%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Biologics Regulatory Affairs Outsourcing Market Size, Share & Trends Analysis Report By Service (Regulatory Consulting), By Phase (Preclinical), By Modality, Phase by Service, Phase by Modality, Modality by Service, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Biologics Regulatory Affairs Outsourcing Market Size, Share & Trends Analysis Report By Service (Regulatory Consulting), By Phase (Preclinical), By Modality, Phase by Service, Phase by Modality, Modality by Service, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
Global Biologics Contract Manufacturing (Biopharma CDMO/Biopharma CMO/Biologics Manufacturing) Market 2022-2035 by Type of Service(s) Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size, and Key Geographical Regions - Product Image

Global Biologics Contract Manufacturing (Biopharma CDMO/Biopharma CMO/Biologics Manufacturing) Market 2022-2035 by Type of Service(s) Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size, and Key Geographical Regions

  • Report
  • 799 Pages
  • Global
From
Biologics Outsourcing Global Market Report 2024 - Product Image

Biologics Outsourcing Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Biologics Contract Development Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Biologics Contract Development Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From
Biologics CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Biologics CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 179 Pages
  • Global
From

About the Biologics Outsourcing Market

The biologics outsourcing market is a subset of the pharmaceutical manufacturing industry, focusing on the production of biologics. Biologics are complex molecules derived from living organisms, such as proteins, antibodies, and vaccines. These molecules are used to treat a variety of diseases, including cancer, autoimmune disorders, and infectious diseases. As biologics become increasingly important in the treatment of these diseases, the demand for biologics outsourcing has grown. Biologics outsourcing involves the transfer of biologics production from the pharmaceutical company to a third-party manufacturer. This allows the pharmaceutical company to focus on the development and marketing of their products, while the third-party manufacturer handles the production. This arrangement also allows the pharmaceutical company to access the latest technologies and expertise in biologics production. Companies in the biologics outsourcing market include Lonza, Boehringer Ingelheim, Merck KGaA, and Fujifilm Diosynth Biotechnologies. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.